Inactive Instrument

THOE HEAL

THRN

US8852601090

Thorne HealthTech, Inc. Reaffirms Sales Guidance for the Full-Year 2022

May 12, 2022 at 01:45 am IST

Thorne HealthTech, Inc. reaffirmed sales guidance for the full-year 2022. For the year, the company expects net sales to be in the range of $240 million to $250 million.

Latest news about THOE HEAL

Thorne Healthtech Announces Innovation Arm Under Thorne Ventures	20/12	CI
Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from NASDAQ Composite Index	16/23/16	CI
L Catterton Partners completed the acquisition of Thorne HealthTech, Inc. from Mitsui & Co., Ltd., Kirin Holdings Company, Limited, Helsinn Therapeutics (U.S.), Inc., Diversified Natural Products, Inc. and others.	16/23/16	CI
Thorne HealthTech, L Catterton Announce Expiration of Oustanding Shares Tender Offer	13/23/13	MT
Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from S&P TMI Index	13/23/13	CI
North American Morning Briefing : Hopes A Mild -2-	12/23/12	DJ
Evercore ISI Downgrades Thorne HealthTech to In Line From Outperform, Raises Price Target to $10.20 From $8	11/23/11	MT
North American Morning Briefing : PCE Inflation -2-	31/23/31	DJ
TD Cowen Downgrades Thorne HealthTech to Market Perform From Outperform, Adjusts Price Target to $10.20 From $8	30/23/30	MT
Sector Update: Health Care Stocks Steady Late Afternoon	29/23/29	MT
Sector Update: Health Care Stocks Rising in Afternoon Trading	28/23/28	MT
Sector Update: Health Care	28/23/28	MT
Beijing's Economic Stimulus Measures Lift US Equity Futures Pre-Bell	28/23/28	MT
Thorne HealthTech Agrees to be Acquired by L Catterton for $10.20 per Share in Cash	28/23/28	MT
L Catterton Partners entered into a definitive agreement to acquire Thorne HealthTech, Inc. from Mitsui & Co., Ltd., Kirin Holdings Company, Limited, Helsinn Therapeutics (U.S.), Inc., Diversified Natural Products, Inc. and others for approximately $620 million.	28/23/28	CI
Thorne Healthtech, Inc. Announces Resignation of Takeshi Minakata from the Board of Directors	17/23/17	CI
Canaccord Genuity Adjusts Price Target on Thorne HealthTech to $7 From $6, Maintains Buy Rating	11/23/11	MT
Transcript : Thorne HealthTech, Inc., Q2 2023 Earnings Call, Aug 08, 2023	09/23/09
Earnings Flash (THRN) THORNE HEALTHTECH Posts Q2 EPS $0.15, vs. Street Est of $0.07	09/23/09	MT
Earnings Flash (THRN) THORNE HEALTHTECH Reports Q2 Revenue $72.7M, vs. Street Est of $68.5M	09/23/09	MT
Thorne Healthtech, Inc. Provides Earnings Guidance for 2023	09/23/09	CI
Thorne HealthTech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
At-home health test maker Thorne explores sale -sources	22/23/22	RE
Sector Update: Health Care Stocks Rising Late Friday	22/23/22	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	21/23/21	MT

Thorne HealthTech, Inc. is a science-driven wellness company that is developing solutions for a personalized approach to health and wellness. The Company's vertically integrated brands, Thorne and Onegevity, provide actionable insights and personalized data, products and services that individuals to take a proactive approach to improve and maintain their health over their lifetime. By combining its multi-omics database, artificial intelligence (AI) and digital health content with its science-backed nutritional supplements, it delivers a total system for wellness. Thorne provides health tests, education, and products that support the optimization of health. Onegevity provides a comprehensive molecular portrait and personalized recommendations for an individual's health, based on integrated analysis of longitudinal blood, genetics and gut microbiome profiles. It offers health tests to generate comprehensive, personalized molecular portraits for its customers.

Sector

More about the company

THOE HEAL

Equities

THRN

US8852601090

Thorne HealthTech, Inc. Reaffirms Sales Guidance for the Full-Year 2022

Latest news about THOE HEAL

Chart THOE HEAL

Company Profile